Contribute Try STAT+ Today

In the latest effort to respond to criticism over drug pricing, Sanofi says it will limit price hikes to a level at or below the medical rate of inflation in the US, which is projected to reach 5.4 percent this year. And like other companies, the drug maker released recent price increases — before and after rebates paid to middlemen —and vowed to continue doing so in the future.

“Beyond hindering access for patients to critical innovations, th[e] complexity [in the pricing system] is undermining the reputation of an entire industry whose purpose is to make a positive change in patients’ lives,” Sanofi chief executive Olivier Brandicourt wrote on the company web site in announcing the new policy on Tuesday. He acknowledged there may be exceptions to the stated policy, though.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.